Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
In Ongoing False Advertising Suit, Judge Allows Natera Counterclaims Against Guardant Health
A federal judge denied four motions by Guardant but granted four others by the company.
NeoGenomics Blood-Based Minimal Residual Disease Test Receives CE Mark
NeoGenomics subsidiary Inivata has also submitted the RaDaR test to the MolDx program in the US for reimbursement.
C2i Genomics, OncoDNA Enter Strategic Alliance for AI-Based Cancer Detection, Monitoring
The companies and the Gustave Roussy Institute plan to initiate a clinical trial to test the utility of escalating treatments for cancers with high risk of recurrence.
Personalis Reports Preliminary Q4 Revenues up More Than 2 Percent
The company is expecting continued growth in its oncology orders in Q4 2021 to translate to significant revenue growth for that business next year.
The company believes its fixed-panel, informatically guided approach can help capture the most possible patients with signs of residual or recurring cancer.
Nov 17, 2021
Nov 4, 2021
Nov 4, 2021
Personalis Q3 Revenues Climb 12 Percent
Nov 3, 2021
Aug 5, 2021
Guardant Health Q2 Revenues Grow 39 Percent
Jul 28, 2021